Archangelicine

(2Z)-2-Méthyl-2-buténoate de 2-[(8S,9R)-9-{[(2Z)-2-méthyl-2-butenoyl]oxy}-2-oxo-8,9-dihydro-2H-furo[2,3-h]chromén-8-yl]-2-propanyle

(8S,9R)-8,9-Dihydro-8-[1-methyl-1-[[(2Z)-2-methyl-1-oxo-2-buten-1-yl]oxy]ethyl]-2-oxo-2H-furo[2,3-h]-1-benzopyran-9-yl (2Z)-2-methyl-2-butenoate

2-[(8S,9R)-9-{[(2Z)-2-Methyl-2-butenoyl]oxy}-2-oxo-8,9-dihydro-2H-furo[2,3-h]chromen-8-yl]-2-propanyl (2Z)-2-methyl-2-butenoate

2-[(8S,9R)-9-{[(2Z)-2-Methyl-2-butenoyl]oxy}-2-oxo-8,9-dihydro-2H-furo[2,3-h]chromen-8-yl]-2-propanyl-(2Z)-2-methyl-2-butenoat

2-Butenoic acid, 2-methyl-, (8S,9R)-8,9-dihydro-8-[1-methyl-1-[[(2Z)-2-methyl-1-oxo-2-buten-1-yl]oxy]ethyl]-2-oxo-2H-furo[2,3-h]-1-benzopyran-9-yl ester, (2Z)-

2607-56-9

Archangelicine

(Z)-2-methylbut-2-enoic acid [(8S,9R)-2-keto-8-[1-methyl-1-[(Z)-2-methylbut-2-enoyl]oxy-ethyl]-8,9-dihydrofuro[2,3-h]chromen-9-yl] ester

(Z)-2-methylbut-2-enoic acid [(8S,9R)-2-keto-8-[1-methyl-1-[(Z)-2-methylbut-2-enoyl]oxy-ethyl]-8,9-dihydrofuro[5,4-h]chromen-9-yl] ester

(Z)-2-methylbut-2-enoic acid [(8S,9R)-8-[1-methyl-1-[(Z)-2-methyl-1-oxobut-2-enoxy]ethyl]-2-oxo-8,9-dihydrofuro[5,4-h]chromen-9-yl] ester

2-[(8S,9R)-9-{[(2Z)-2-METHYLBUT-2-ENOYL]OXY}-2-OXO-2H,8H,9H-FURO[2,3-H]CHROMEN-8-YL]PROPAN-2-YL (2Z)-2-METHYLBUT-2-ENOATE

[(8S,9R)-8-[1-methyl-1-[(Z)-2-methylbut-2-enoyl]oxy-ethyl]-2-oxo-8,9-dihydrofuro[5,4-h]chromen-9-yl] (Z)-2-methylbut-2-enoate

[(8S,9R)-8-[2-[(Z)-2-methylbut-2-enoyl]oxypropan-2-yl]-2-oxo-8,9-dihydrofuro[5,4-h]chromen-9-yl] (Z)-2-methylbut-2-enoate

Archangelicin

Neuropeptide Y receptor type 1

NPY1R_HUMAN